Inhibikase Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Inhibikase Therapeutics has a total shareholder equity of $5.1M and total debt of $177.3K, which brings its debt-to-equity ratio to 3.5%. Its total assets and total liabilities are $8.8M and $3.7M respectively.
Key information
3.5%
Debt to equity ratio
US$177.26k
Debt
Interest coverage ratio | n/a |
Cash | US$7.94m |
Equity | US$5.10m |
Total liabilities | US$3.73m |
Total assets | US$8.83m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: IQT0's short term assets ($8.6M) exceed its short term liabilities ($3.7M).
Long Term Liabilities: IQT0's short term assets ($8.6M) exceed its long term liabilities ($25.6K).
Debt to Equity History and Analysis
Debt Level: IQT0 has more cash than its total debt.
Reducing Debt: IQT0 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IQT0 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: IQT0 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 46.1% each year